Drugs / sulopenem etzadroxil

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) ORLYNVAH 2024-10-25 fda.gov

Trials 7 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT07092813 Apr → Oct 2026 expected Iterum Therapeutics, International Limited Recruiting No outcome recorded
Phase 1 NCT04700787 Apr 2021 → Mar 2022 acute pyelonephritis, infectious peritonitis Iterum Therapeutics, International Limited Withdrawn No outcome recorded
Phase 1 NCT00759564 Nov 2008 → Mar 2010 pneumonia Pfizer Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00797108 Jan → Jun 2009 bacterial pneumonia Pfizer Completed No outcome recorded
Phase 32 trials
Phase 3 NCT05584657 Oct 2022 → Nov 2023 cystitis, urinary tract infection Iterum Therapeutics, International Limited Completed No outcome recorded
Phase 3 NCT03358576 Sep 2018 → Oct 2019 intestinal infectious disease Iterum Therapeutics, International Limited Completed No outcome recorded
Phase not stated1 trial
NCT04682834 acute pyelonephritis Iterum Therapeutics, International Limited No longer available No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as sulopenem etzadroxil “The following day, patients will receive a single dose of 500 mg of sulopenem etzadroxil and 500 mg of probenecid given orally as a bilayer tablet.” NCT04700787
4

NCT03358576

NCT05584657

NCT07092813

NCT04682834

Known as PF-03709270 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00797108
1

NCT00759564

Known as Sulopenem etzadroxil component of orlynvah ChEMBL registry synonym — accepted as the source's own label CHEMBL4594246
Modality Small molecule “Sulopenem is a broad-spectrum penem β-lactam antibiotic” NCT07092813
Route Oral “single oral dose of PF-03709270 (1000 mg)” NCT00759564